Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 4/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GRB2 | P62993 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24096004 | 0.85 | ECE1 (0.38) | ECE1CPB2PDCD1LG2CD274HDAC2 | |
| SCHEMBL13599664 | 0.82 | MAPT (0.40) | CPB2 | |
| SCHEMBL17159700 | 0.80 | ECE1 (0.46) | ECE1ALDH1A1 | |
| SCHEMBL17159699 | 0.80 | ECE1 (0.46) | ECE1ALDH1A1 | |
| SCHEMBL23695825 | 0.79 | HDAC2 (0.34) | HDAC2POLB | |
| SCHEMBL1634160 | 0.78 | ECE1 (0.36) | ECE1 | |
| SCHEMBL19483456 | 0.78 | ECE1 (0.36) | ECE1 | |
| Hydrochloric Acid SCHEMBL20789044 | 0.78 | ECE1 (0.45) | ECE1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7805757 | 0.78 | ECE1 (0.45) | ECE1ALDH1A1 | |
| SCHEMBL18902807 | 0.78 | ECE1 (0.37) | ECE1HDAC2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779090-B2 | Methods and compositions for the treatment of heart failure and other disorders | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120283411-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120088902-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120040892-A9 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2012-02-16 | — | — | US | disclosed |
| US-20110021419-A1 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | Ironwood Pharmaceuticals Inc. | 2011-01-27 | — | — | US | disclosed |
| US-20090305993-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090192083-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | IRONWOOD PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021419-A1 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | GCGR, GCG, GIPR | ECE1 783/4885CPB2 554/4885PDCD1LG2 4663/4885 |
| US-20120040892-A9 | Methods and Compositions for the Treatment of Heart Failure and Other Disorders | GCGR, GCG, GIPR | ECE1 783/4885CPB2 554/4885PDCD1LG2 4663/4885 |
| US-20120088902-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GRPR, GCGR, GIPR | ECE1 3617/4885CPB2 2011/4885PDCD1LG2 2381/4885 |
| US-20120283411-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GRPR, GCGR, GIPR | ECE1 3617/4885CPB2 2011/4885PDCD1LG2 2381/4885 |
| US-20090192083-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GRPR, GCGR, GIPR | ECE1 2868/4885CPB2 1642/4885PDCD1LG2 2018/4885 |
| US-20090305993-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GIPR, VIP, GCGR | ECE1 1040/4885CPB2 305/4885PDCD1LG2 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.